News | Cath Lab | May 29, 2018

FAME 2, DANAMI-3-PRIMULTI and COMPARE-ACUTE FFR-guided PCI vs. Medical Therapy Improves Outcomes

Results from the first patient-level pooled analysis of all existing trials comparing FFR-guided PCI with contemporary stents versus medical therapy demonstrates a reduction in cardiac events

FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.

May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable coronary lesions to improve hard outcomes. Stable lesions include both patients with stable coronary artery disease as well as non-culprit lesions in hemodynamically stabilized acute coronary syndrome (ACS) patients.

Three randomized controlled trials have compared fractional flow reserve (FFR)-guided PCI using modern drug-eluting stents versus medical therapy for stable lesions: FAME 2, DANAMI-3-PRIMULTI, and COMPARE-ACUTE. A new pooled analysis of these trials showed FFR does reduce cardiac deaths and heart attacks. The results were presented at EuroPCR 2018 last week.

Each study demonstrated a clinical benefit in favor of FFR-guided PCI, including urgent revascularization in the primary endpoint. However, each trial by itself was not powered for the endpoint of cardiac death or myocardial infarction. For this reason, a pooled, patient-level analysis including 2,400 patients was performed to address adequately whether FFR-guided modern PCI reduces cardiac death or myocardial infarction versus medical therapy.

This is the first pooled analysis on a patient level which includes all existing trials comparing FFR-guided PCI with contemporary stents versus medical therapy. In addition, this analysis extended follow-up for both the FAME 2 and DANAMI-3-PRIMULTI trials.

“Our results show for the first time that modern PCI, when guided by FFR, reduces so-called 'hard endpoints' – the composite outcome of cardiac death or myocardial infarction – when compared to an initial strategy using medical therapy," explained Frederik M. Zimmermann, M.D., ​Department of Cardiology, Catharina Hospital Eindhoven, The Netherlands. "Importantly, we found a relative risk reduction of approximately 30 percent when using FFR-guided treatment, which corresponded to an estimated absolute risk reduction of about 4.5 percent at five years. Our analyses also favored FFR-guided PCI when examining the composite of all-cause death or myocardial infarction. Differences between groups were driven by a reduction in myocardial infarction. No differences were observed for deaths from cardiac causes or deaths from any cause."

What role do innovation, devices or technology play in these results?

This pooled analysis demonstrates that key technology innovations (pressure wire fractional flow reserve to guide PCI and contemporary drug-eluting stents) have enabled PCI to improve patient outcomes.

“In patients with stable coronary lesions, contemporary PCI – i.e., guided by FFR – reduces the risk of future myocardial infarction or cardiac death independently of its impact on symptoms,” Zimmermann said. 

Key Data

   • 2,400 patients in pooled, patient-level analysis from FAME 2, DANAMI-3-PRIMULTI, and COMPARE-ACUTE trial

   • FFR-guided modern PCI versus optimal medical therapy

   • 30 percent approximate relative risk reduction of the composite of cardiac death or myocardial infarction using FFR-guided treatment, corresponding to an estimated absolute risk reduction of ~4.5% at 5 years.
Contact information

 

Links to other 2018 EuroPCR late-breaking trials

 

#EuroPCR 


Related Content

News | Cardiac Diagnostics

September 15, 2022 - Happitech has announced the launch of its FastStart Research app. The Amsterdam-based digital ...

Home September 15, 2022
Home
Feature | Cardiac Diagnostics | by Kelly Patrick

Like most healthcare markets, the diagnostic cardiology market has had a bumpy ride in recent years. The COVID-19 ...

Home August 23, 2022
Home
Feature | Cardiac Diagnostics | By Adam Saltman, MD, PhD

Before opining on the future of cardiac health, I think it’s important to define what “cardiac health” actually is. If ...

Home May 04, 2022
Home
News | Cardiac Diagnostics

January 31, 2022 — Scientists have developed an artificial intelligence (AI) system that can analyze eye scans taken ...

Home January 31, 2022
Home
News | Cardiac Diagnostics

November 10, 2021 — Abbott released new global market research from its Beyond Intervention initiative, the company’s ...

Home November 10, 2021
Home
Feature | Cardiac Diagnostics | By Dave Fornell, DAIC Editor

October 29, 2021 — A new guideline for the evaluation and diagnosis of chest pain was released this week that provides ...

Home October 29, 2021
Home
News | Cardiac Diagnostics

October 4, 2021 – Nanowear, a hospital-at-home and remote diagnostic platform that used proprietary wearable cloth ...

Home October 04, 2021
Home
News | Cardiac Diagnostics

September 28, 2021 — Biotricity Inc., a medical diagnostic and consumer healthcare technology company, has developed a ...

Home September 28, 2021
Home
News | Cardiac Diagnostics

July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation ...

Home July 29, 2021
Home
News | Cardiac Diagnostics

July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc. second-generation ...

Home July 01, 2021
Home
Subscribe Now